STOCK TITAN
  1. Home
  2. Sec-filings
  3. RMD
  4. [Form 4] RESMED INC Insider Trading Activity

ResMed (RMD) CEO Michael Farrell sells 4,991 shares after option exercise

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

ResMed Inc. Chairman and CEO Michael J. Farrell reported an option exercise and share sale. On 12/08/2025, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, converting them into the same number of common shares.

On the same date, he sold 4,991 ResMed common shares at a weighted average price of $251.4117 per share under a Rule 10b5-1 trading plan adopted on October 31, 2024. After these transactions, he directly owned 466,223 ResMed shares, held 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust, and beneficially owned 54,903 stock options with underlying ResMed shares.

Positive

  • None.

Negative

  • None.
Insider Farrell Michael J.
Role Chairman and CEO
Sold 4,991 shs ($1.25M)
Type Security Shares Price Value
Exercise ResMed Common Stock Options 4,991 $0.00 --
Exercise ResMed Common Stock 4,991 $146.34 $730K
Sale ResMed Common Stock 4,991 $251.4117 $1.25M
holding ResMed Common Stock -- -- --
Holdings After Transaction: ResMed Common Stock Options — 54,903 shares (Direct); ResMed Common Stock — 471,214 shares (Direct); ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)
Footnotes (1)
  1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. This transaction was executed in multiple trades at prices ranging from $249.63 - $255.775. The price reported above reflects the weighted average sale price. Represents date options first become exercisable. Options vest 1/3 per year.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Farrell Michael J.
(Last) (First) (Middle)
RESMED INC.
9001 SPECTRUM CENTER BLVD
(Street)
SAN DIEGO CA 92123
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chairman and CEO
3. Date of Earliest Transaction (Month/Day/Year)
12/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
ResMed Common Stock 12/08/2025 M(1) 4,991 A $146.34 471,214 D
ResMed Common Stock 12/08/2025 S(1) 4,991 D $251.4117(2) 466,223 D
ResMed Common Stock 2,090 I Lisette and Michael Farrell Family Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
ResMed Common Stock Options $146.34 12/08/2025 M(1) 4,991 11/11/2020(3) 11/21/2026 ResMed Common Stock 4,991 $0 54,903 D
Explanation of Responses:
1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
2. This transaction was executed in multiple trades at prices ranging from $249.63 - $255.775. The price reported above reflects the weighted average sale price.
3. Represents date options first become exercisable. Options vest 1/3 per year.
/s/ Michael J. Farrell, Chairman and CEO 12/09/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ResMed (RMD) report for its CEO?

ResMed reported that Chairman and CEO Michael J. Farrell exercised 4,991 stock options at $146.34 per share and sold 4,991 common shares on 12/08/2025.

At what prices did Michael Farrell exercise and sell ResMed (RMD) shares?

He exercised options at an exercise price of $146.34 per share and sold shares at a weighted average price of $251.4117 per share, with individual trades between $249.63 and $255.775.

Was the ResMed (RMD) CEO transaction under a Rule 10b5-1 plan?

Yes. The filing states the transaction was conducted under a Rule 10b5-1 trading plan that was adopted on October 31, 2024.

How many ResMed (RMD) shares does Michael Farrell own after this Form 4?

After the reported transactions, Michael Farrell directly owned 466,223 ResMed common shares and indirectly owned 2,090 shares through the Lisette and Michael Farrell Family Trust.

How many ResMed (RMD) stock options does the CEO still hold?

Following the option exercise and sale, he beneficially owned 54,903 ResMed common stock options, with underlying ResMed shares.

When do the ResMed (RMD) CEO stock options vest and expire?

The exercised options first became exercisable on 11/11/2020, vesting one-third per year, and have an expiration date of 11/21/2026.